Medical Marijuana, Inc. Investment AXIM(R) Biotechnologies, Inc. Secures Funding to Continue Pharma Clinical Trials Program in Cannabinoid R&D

Financing Enables Cannabinoid Innovator to Continue Phase I-II Trials Of Numerous Intellectual Property (IP) Protected Cannabinoid-Based Products for Multiple Indications SAN DIEGO, CA AXIM, MJNA, (Marketwired October 26, 2016) Medical Marijuana, Inc. (OTC PINK: MJNA) today announced that its portfolio company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, has secured private funding to continue its pharmaceutical clinical trials program in cannabinoid research and development for multiple indications. AXIM® Biotech s most
http://bit.ly/2ffIhoy